RSV strikes early, but you can strike first. No Infant Left Unprotected: Action-Ready Strategies for RSV Season 2025-26 is a concise, case-based lesson that distills NACI’s universal-immunization guidance, the season-long ...

Respiratory syncytial virus (RSV) remains the leading cause of hospitalization in Canadian infants. While hospital-based administration of nirsevimab may be addressing in-season births in many regions in Canada, many infants ...

A rising number of Canadians suffer from chronic inflammatory skin conditions, such as atopic dermatitis, seborrheic dermatitis, and plaque psoriasis. This program supports clinicians in understanding the burden of these ...

Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants under 12 months, yet many infants born outside of the RSV season are unintentionally missed by hospital-based prevention ...

A fertility healthcare professional (HCP) is part of an interdisciplinary team that supports treatment of people experiencing difficulties with conception and reproductive disorders. Reproductive health is a demanding field, and ...

As the GLP1 therapy landscape shifts in 2026, clinical success is being redefined by more than just numbers on a scale. Join Dr. Sean Wharton for an essential update on ...

With the recent authorization of fezolinetant and elinzanetant for VMS by Health Canada, it is important that clinicians understand the associated monitoring requirements. This module focuses on the specific safety ...

Welcome to this foundational module on the evolving landscape of vasomotor symptom (VMS) management. To effectively manage VMS, it’s crucial to first understand the underlying biological mechanisms. This module will ...

In recent years, the landscape of non-hormonal drugs for VMS has expanded significantly, offering alternatives for women who are contraindicated or prefer not to use hormone therapy (HT). This module ...